



Roche (Nutley, NJ, USA) has announced the appointment of **Pamela Carroll** (left) as Nutley oncology discovery site head and global lead, pathways biology within the company's Pharma Research and Early Development (pRED) division. She joins Roche from the Belfer Institute of Applied Cancer Sciences at Dana-Farber Cancer Institute, Harvard Medical School, where she was head of research.

"With more than a decade's industry experience concentrated in cancer, Pam has built a reputation for scientific excellence and leadership in the field," says Mike Burgess, global head, oncology discovery and translational area and head, large-molecule research at Roche. "Her broad knowledge and successful history in leading oncology drug discovery efforts make her an ideal fit for this position."

Jason M. Aryeh, founder and general partner of private hedge fund JALAA Equities, has been elected to the board of directors of Myrexis (Salt Lake City, UT, USA), bringing the total of board members to seven. Aryeh also serves on the boards of Ligand Pharmaceuticals, Nabi Biopharmaceuticals and CorMatrix Cardiovascular.

Karo Bio (Huddinge, Sweden) has appointed **Per Bengtsson** CEO. He had been acting CEO and a member of the board since May. He previously served as medical director and therapeutic area head at Ferring, CEO of Probi and development manager at Bionor Immuno.

Marinomed Biotechnologie (Vienna) has announced the appointment of 15-year industry veteran **Angelika Bodenteich** as the company's new head of development. She joins Marinomed from Onepharm Research & Development, where she held the position of chief medical officer for the last two years and head of development for one year prior to that.

Tim Hall has been named finance director for Oxford Gene Technology (Oxford, UK). He has worked in the pharmaceutical and medical device industries for over 20 years, most recently serving in the same position at Lombard Medical Technologies.

Prometheus Laboratories (San Diego) has named **Peter Heseltine** as senior vice president and chief medical officer. Heseltine joins the company with almost 35 years of experience in the healthcare field. Most recently, he served as vice president and medical director of global businesses at **Beckman Coulter**.

David Huang has joined ContraFect (Yonkers, NY, USA) as chief medical officer. He most recently served as global medical director of medical affairs for Pfizer. Previously, he was associate director of clinical development for Boehringer Ingelheim.

Genentech (S. San Francisco, CA, USA) chairman and former CEO **Arthur Levinson** has been named nonexecutive chairman of the board of Apple (Cupertino, CA, USA), filling the vacancy left when Apple's co-founder Steve Jobs died in October after battling pancreatic cancer. Levinson, who has served on Apple's board since 2000, most recently served as its co-lead director along with Andrea Jung, CEO of Avon.

Ambit Biosciences (San Diego) has announced the appointment of **Michael A. Martino** as president, CEO and member of the board of directors, succeeding **Alan Lewis**. Martino brings a nearly 30-year track record in leading life sciences companies, most recently serving as senior vice president and general manager of diagnostics and senior vice president of innovation, business development and strategy at CareFusion. He has also served as CEO of Arzeda and Sonus Pharmaceuticals.

Sanofi (Paris) has announced the appointment of **David Meeker** as CEO of Genzyme (Cambridge, MA, USA), a Sanofi company. Meeker joined Genzyme in 1994 as medical director to work on the cystic fibrosis gene therapy program and rose to become COO in 2009. Under his leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise. Previous

Genzyme divisions—renal, biosurgery and oncology—have been integrated within the existing Sanofi portfolio giving them greater global scale and capabilities. To lead the new divisions, Genzyme has announced the appointment of **William "Bill" Sibold** as head of multiple sclerosis and **Rogério Vivaldi** as head of rare diseases. Sibold has more than 20 years of experience in the biopharma industry, most recently as chief commercial officer at Avanir Pharmaceuticals. Previously, he was senior vice president of Biogen Idec's US commercial operations. Vivaldi joined Genzyme in 1997 and was most recently president of the renal and endocrinology business.

Stephen J. Peroutka has been appointed executive vice president and chief medical officer of NeurogesX (San Mateo, CA, USA). He previously joined the company as a part-time consultant. Most recently, Peroutka was vice president, scientific affairs at PRA, a global clinical research organization. He was previously CMO of Zogenix.

Catalyst Pharmaceutical Partners (Coral Gables, FL, USA) has named **Richard P. Rieger** to the newly created position of vice president, commercial operations. He joins Catalyst from PhaseRx, where he served as vice president, business development and leader of the company's commercial initiatives. Previously, Rieger was vice president, business development at Dendreon.

Maurizio Voi has been named chief medical officer and chief development officer at Curis (Lexington, MA, USA). Voi was most recently vice president of clinical development and medical affairs for the oncology business unit at Pfizer Global R&D.

Novavax (Rockville, MD, USA) has named **Russell P. "Rip" Wilson** as senior vice president of business development. He was most recently CFO at Supernus Pharmaceuticals and was previously senior vice president, CFO and general counsel of Iomai. In addition, **Erica Shane** has been appointed vice president, process development. Before joining Novavax, Shane was senior director of bioprocess engineering at MedImmune.